Clinical Impact and Cost-Effectiveness of Xpert MTB/RIF Testing in Hospitalized Patients with Presumptive Pulmonary Tuberculosis in the United States | Zendy

James Cowan | Zendy; Aldine S. Chandler | Zendy; Elizabeth Kracen | Zendy; David R. Park | Zendy; Carolyn K. Wallis | Zendy; Emelline Liu | Zendy; Chao Song | Zendy; David H. Persing | Zendy; Ferric C. Fang | Zendy

Open Access

Clinical Impact and Cost-Effectiveness of Xpert MTB/RIF Testing in Hospitalized Patients with Presumptive Pulmonary Tuberculosis in the United States

Author(s) -

James Cowan,

Aldine S. Chandler,

Elizabeth Kracen,

David R. Park,

Carolyn K. Wallis,

Emelline Liu,

Chao Song,

David H. Persing,

Ferric C. Fang

Publication year - 2016

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciw803

Subject(s) - medicine , pulmonary tuberculosis , tuberculosis , intensive care medicine , pathology

Microscopic examination of acid-fast-stained sputum smears is the current standard of care in the United States to determine airborne infection isolation (AII) of inpatients with presumptive pulmonary tuberculosis (PTB). However, nucleic acid amplification testing (NAAT) with the Xpert MTB/RIF assay (Xpert) may be more efficient and less costly.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research